samedan logo
 
 
 
spacer
home > ebr > summer 2007 > small but perfectly formulated
PUBLICATIONS
European Biopharmaceutical Review

Small but Perfectly Formulated

The total US market for nanomedicines will command strong growth over the long term, rising to over $39 billion in 2011, says William Martineau at Freedonia Group, sustaining a strong upward pace to $82 billion in 2016

Trends in the US pharmaceutical industry will favour the increasing development of nanotechnology drug formulations and delivery systems. The high costs and extensive regulatory requirements involved in commercialising new therapies will prompt proprietary pharmaceutical manufacturers to diversify research and development strategies into product line extensions. Reformulations and drug delivery systems provide a costeffective means to improve the safety, efficacy and convenience of existing medication. In most cases, improved versions of existing medication are subject to less stringent clinical testing standards than new therapies. As a result, the commercialisation timetable is shorter and less costly. More importantly, a multiple source drug adapted to a unique delivery system can sometimes gain new or extended patent protection, providing its developer with significant competitive advantages.

Nanomedicines are pharmaceuticals and biologicals composed of nanoscale active ingredients or adapted to nanoparticle delivery systems. Monoclonal antibodies comprise the principal nanoscale active ingredients now employed in therapeutic applications and 20 such therapies have been approved for use by the FDA. In addition, more than 150 new monoclonal antibody drugs are being tested in US clinical trials. In commercial use, nanoparticle drug delivery agents consist of crystals, liposomes and polymers. Dendrimers, fullerenes, micelles, nanoshells and nanowires are among the nanoparticle drug delivery agents in various stages of development.

MONOCLONAL ANTIBODIES

Discovered in the mid-1970s, monoclonal antibodies meet the definition of nanomaterials, being on average just 20 nanometres in size. They are protein molecules produced through hybridoma technology. A hybridoma is a biological manufacturing factory created by fusing together two cells of different origins. One cell incorporates a gene that stimulates the production of an antibody specific to a single target, such as an antigen or antigen receptor site. The other cell is derived from a mouse and contains an indestructible, continuously dividing tumour. The fused hybridoma produces an unlimited supply of monoclonal antibodies that will respond or react to only one specific stimuli.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
William Martineau is an authority on the health care industry. He has performed in-depth research across biotechnology, pharmaceuticals, medical packaging and related areas, producing titles such as: Pharmaceutical Chemicals, US Pharmaceutical Packaging, World Pharmaceutical Packaging, World Pharmaceuticals I & II, Medical Testing Chemicals, Drug Delivery Systems, and Biotechnology. Prior to joining Freedonia, he was Manager of Market Development at American Sterilizer Company, where he gained experience in health care research and strategic planning. At Invenex Laboratories, he served as Product Manager, responsible for the administration of a line of injectable pharmaceuticals. He also served as Senior Health Care Analyst at Predicasts Inc and Manager of Market Research at Life Technologies Inc (a division of The Dexter Corporation). William holds a BA in Management and an MBA in Marketing and Finance from Kent State University.
spacer
William Martineau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Creating your Secondary Packaging Strategy

Pharmaceutical and biotechnology companies with a drug product in clinical development are usually focused on a quick commercial launch. Secondary packaging aspects are often less considered. Correlations with secondary packaging (in this context, secondary packaging also includes device assembly and serialization) that are not considered in this phase can have a negative effect on: · further processability · options in the product lifecycle management · cost and time-to-market
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement